

#28/ I.D.S. (Entered)

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/747,521
Filing Date	December 21, 2000
First Named Inventor	Galloway
Art Unit	1645
Examiner Name	Shahnan Shah
Attorney Docket Number	22727/04079

RECEIVED**JUL 14 2004****OFFICE OF PETITION**

Sheet 1 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ARORA et al., "Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells", <u>J. Biol. Chem.</u> (1992) Volume 267, Pages 15542-15548.	
		ARORA and LEPLA, "Residues 1-254 of anthrax toxin lethal factor sufficient to cause cellular uptake of fused polypeptides", <u>J. Biol. Chem.</u> (1993) Volume 268, Pages 3334-3341.	
		BROSSIER et al., "Role of toxin functional domains in anthrax pathogenesis", <u>Infect. Immun.</u> (2000) Volume 68, Pages 1781-1786.	
		CIRINO et al., "Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors", <u>Infect. Immun.</u> (1999) Volume 67, Pages 2657-2963.	
		DENIS-MIZE et al., "Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A", <u>FEMS Immunol. Med. Microbiol.</u> (2000) Volume 24, Pages 147-154.	
		DONNELLY et al., "DNA Vaccines", <u>Annu. Rev. Immunol.</u> (1997) Volume 15, Pages 617-648.	
		DUESBERY et al., "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor", <u>Science</u> (1998) Volume 280, Pages 734-737.	
		FELLOWS et al., "Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographic origin", <u>Vaccine</u> (2001) Volume 19, Pages 3241-3247.	
		FELTQUATE et al., "Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization", <u>J. Immunol.</u> (1997) Volume 158, Pages 2278-2284.	
		FRIEDLANDER, "Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process", <u>J. Biol. Chem.</u> (1986) Volume 261, Pages 7123-7126.	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/747,521
Filing Date	December 21, 2000
First Named Inventor	Galloway
Art Unit	1645
Examiner Name	Shahnan Shah
Attorney Docket Number	22727/04079

RECEIVED

JUL 14 2004

OFFICE OF PETITIONS

Sheet 2 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GORDON et al., "Proteolytic activation of a bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases", <u>Infect. Immun.</u> (1995) Volume 63, Pages 82-87.	
		GUIDI-RONTANI et al., "Anthrax lethal toxin-induced mitogenic response of human T-cells", <u>FEMS Lett.</u> (1997) Volume 157, Pages 285-289.	
		GUIDI-RONTANI et al., "Germination of Bacillus anthracis within alveolar macrophages", <u>Mol. Microbiol.</u> (1999) Volume 31, Pages 9-17.	
		GUPTA et al., "Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis", <u>Biochem. Biophys. Res. Commun.</u> (2001) Volume 280, Pages 158-163.	
		HADDAD et al., "Comparative study of DNA-based immunization vectors: Effect of secretion signals on the antibody response in mice", <u>FEMS Immunol. Med. Microbiol.</u> (1997) Volume 18, Pages 193-202.	
		IVINS et al., "Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs", <u>Vaccine</u> (1995) Volume 13, Pages 1779-1784.	
		IVINS and WELKOS, "Recent advances in the development of an improved, human anthrax vaccine", <u>Eur. J. Epidemio.</u> (1988) Volume 4, Pages 12-19.	
		KLIMPEL et al., "Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin", <u>Proc. Natl. Acad. Sci. USA</u> (1992) Volume 89, Pages 10277-10281.	
		KLIMPEL et al., "Anthrax toxin lethal factor contains a zinc metalloproteinase consensus sequence which is required for lethal toxin activity", <u>Mol. Microbiol.</u> (1994) Volume 13, Pages 1093-1100.	
		LEPPLA, "Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells", <u>Proc. Natl. Acad. Sci. USA</u> (1982) Volume 79, Pages 3162-3166.	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/747,521
Filing Date	December 21, 2000
First Named Inventor	Galloway
Art Unit	1645
Examiner Name	Shahnan Shah
Attorney Docket Number	22727/04079

RECEIVED**JUL 14 2004****OFFICE OF PETITIONS**

Sheet 3

of

4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LEPPLA, "Production and purification of anthrax toxin", <u>Methods Emzymol.</u> (1988) Volume 165, Pages 103-116.	
		LEPPLA et al., "Proteolytic activation of anthrax toxin bound to cellular receptors", <u>Bacterial protein toxins</u> (F.J. Fehrenbach et al., Gustav Fischer, New York, NY) Pages 111-112.	
		LITTLE and IVINS, "Molecular pathogenesis of Bacillus anthracis infection", <u>Microbes Infect.</u> (1999) Volume 2, Pages 131-139.	
		LITTLE et al., "Production and characterization of monoclonal antibodies to the protective antigen of Bacillus anthracis toxin", <u>Infect. Immun.</u> (1988) Volume 56, Pages 1807-1813.	
		MANICKAN et al., "DNA vaccines a modern gimmick or a boon to vaccinology?", <u>Crit. Rev. Immunol.</u> (1997) Volume 17, Pages 139-154.	
		MIKESELL et al., "Evidence for plasmidmediated toxin production in Bacillus anthracis", <u>Infect. Immun.</u> (1983) Volume 39, Pages 371-376.	
		MILNE et al., "Anthrax protective antigen forms oligomers during intoxication of mammalian cells", <u>J. Biol. Chem.</u> (1994) Volume 269, Pages 20607-20612.	
		PANNIFER et al., "Crystal structure of the anthrax lethal factor", <u>Nature</u> (2001) Volume 414, Pages 229-233.	
		PARK and LEPPLA, "Optimized production and purification of Bacillus anthracis lethal factor", <u>Protein Expr. Purif.</u> (2000) Volume 18, Pages 293-302.	
		PELLIZARI et al., "Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the KOS.UFB-induced release of NO and TNF", <u>FEBS Lett.</u> (1999) Volume 462, Pages 199-204.	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/747,521
Filing Date	December 21, 2000
First Named Inventor	Galloway
Art Unit	1645
Examiner Name	Shahnan Shah
Attorney Docket Number	22727/04079

RECEIVED**JUL 14 2004****OFFICE OF PETITIONS**

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PETOSA et al., "Crystal structure of the anthrax toxin protective antigen", <u>Nature</u> (1997) Volume 385, Pages 833-838.	
		PEZARD et al., "Contribution of individual toxin components to virulence of <i>Bacillus anthracis</i> ", <u>Infect. Immun.</u> (1991) Volume 59, Pages 3472-3477.	
		PEZARD et al., "Protective immunity induced by <i>Bacillus anthracis</i> toxin-deficient strains", <u>Infect. Immun.</u> (1995) Volume 63, Pages 1369-1372.	
		PRICE, "Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein", <u>Infect. Immun.</u> (2001) Volume 69, Number 7, Pages 4509-4515.	
		SINGH et al., "The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor", <u>J. Biol. Chem.</u> (1994) Volume 269, Pages 29039-29046.	
		VARUGHESE et al., "Internalization of a <i>Bacillus anthracis</i> protective antigen c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies", <u>Mol. Med.</u> (1998) Volume 4, Pages 87-95.	
		VITALE et al., "Anthrax lethal factor cleaves the N-terminus of MAPKK and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages", <u>Biochem. Biophys. Res. Commun.</u> (1998) Volume 248, Pages 706-711.	
		WELKOS et al., "Sequence and analysis of the DNA encoding protective antigen of <i>Bacillus anthracis</i> ", <u>Gene</u> (1988) Volume 69, Pages 287-300.	
		ZAUCHA et al., "The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation", <u>Arch. Pathol. Lab. Med.</u> (1998) Volume 122, Pages 982-992.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.